FDA: There is no reason to restrict the continued use of fluoropolymers in medical devices.
What happens when pressure to eliminate a material creates greater risk for the patient?
This Deep Dive examines the growing regulatory tension around PFAS and medical-device fluoropolymers, and why evaluating substitution requires more than asking whether a material belongs to a broad chemical category.
Key highlights covered in the audio:
* Not all PFAS present the same risk. The discussion distinguishes small-molecule PFAS from large, biostable fluoropolymers such as PTFE and PVDF used in medical devices.
* FDA’s position is supported by extensive clinical experience. Decades of use and a large ECRI review found no conclusive evidence of patient harm from PTFE.
* Substitution can introduce new clinical hazards. Changes in friction, flexibility, chemical resistance, sealing, or coating integrity can directly affect device performance and patient safety.
* This creates a substitution risk paradox. Eliminating one perceived material hazard may introduce more immediate risks such as reduced trackability, altered drug delivery, particulate shedding, or embolic complications.
* The decision belongs inside risk management. Under ISO 14971, the key question is how substitution changes the device’s total risk profile—not simply whether the original material can be removed.
* A defensible strategy requires evidence. Chemical characterization, toxicological assessment, clinical evidence, and post-market surveillance can support continued use of a proven material.
Keywords:
PFAS, Fluoropolymers, PTFE, Medical Devices, FDA, Material Substitution, ISO 14971, Benefit-Risk Assessment, Patient Safety, Risk Management
🎧 Listen to the Deep Dive for a closer look at why eliminating a perceived material hazard does not necessarily reduce the overall risk of a medical device.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.
Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026). PFAS in Medical Devices: What You Need to Know, FDA Web Resource, U.S. Food and Drug Administration
* Regulatory Affairs Group (2026). EU PFAS Restriction for Medical Devices: REACH Timelines and Derogations, Strategic Industry Report, MedTech Regulatory Guide
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe
